Cargando…

A rapid and durable response to cabozantinib in an osimertinib-resistant lung cancer patient with MET D1228N mutation: a case report

Osimertinib has efficacy superior to that of standard epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for the first-line treatment of patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, patients treated with osimertinib eventually acquire drug re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuang, Yukun, Wang, Jiyu, Xu, Peihang, Zheng, Yifan, Bai, Lihong, Sun, Xue, Li, Zimu, Gan, Runjing, Li, Huixia, Ke, Zunfu, Tang, Kejing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422132/ https://www.ncbi.nlm.nih.gov/pubmed/34532491 http://dx.doi.org/10.21037/atm-21-3861

Ejemplares similares

Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC
por: Kuang, Yukun, et al.
Publicado: (2021)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study
por: Li, Huixia, et al.
Publicado: (2023)

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
por: Jóri, Balázs, et al.
Publicado: (2023)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
por: Tang, Kejing, et al.
Publicado: (2018)

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2021)

Infantile fibrosarcoma–like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib
por: Gupta, Ajay, et al.
Publicado: (2020)

Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
por: Sachkova, Anastasia A., et al.
Publicado: (2022)

Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification
por: Sang, Yun Beom, et al.
Publicado: (2023)

Ion selectivity and gating behavior of the CorA-type channel Bpss1228
por: Zhu, Yibo, et al.
Publicado: (2022)

Enrichment of c-Met(+) tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib
por: Liu, L, et al.
Publicado: (2014)

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
por: Daud, Adil, et al.
Publicado: (2017)

Cabozantinib Inhibits Photodynamic Therapy-Induced Auto- and Paracrine MET Signaling in Heterotypic Pancreatic Microtumors
por: Broekgaarden, Mans, et al.
Publicado: (2020)

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
por: Hage, C, et al.
Publicado: (2013)

Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model
por: Sun, Yinggang, et al.
Publicado: (2015)

Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
por: Hagege, Anais, et al.
Publicado: (2022)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

Cabozantinib, a Multityrosine Kinase Inhibitor of MET and VEGF Receptors Which Suppresses Mouse Laser-Induced Choroidal Neovascularization
por: Zhang, Xiaoli, et al.
Publicado: (2020)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
por: Cekay, Michael, et al.
Publicado: (2023)

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature
por: Economides, Minas P., et al.
Publicado: (2020)

Complete genome sequence of Thermosediminibacter oceani type strain (JW/IW-1228P(T))
por: Pitluck, Sam, et al.
Publicado: (2010)

Restoration of miR-1228* Expression Suppresses Epithelial-Mesenchymal Transition in Gastric Cancer
por: Jia, Litao, et al.
Publicado: (2013)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor
por: Hara, Takahito, et al.
Publicado: (2020)

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
por: Merkhofer, Cristina M., et al.
Publicado: (2021)

Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report
por: Zhao, Nan, et al.
Publicado: (2022)

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer
por: Urbanska, Edyta M., et al.
Publicado: (2022)

1228. Incidence of Staphylococcus aureus Infection after Elective Surgeries Among Adults in US Hospitals
por: Dreyfus, Jill, et al.
Publicado: (2018)

1228. Risk Factors for Contamination with Carbapenemase-Producing Enterobacteriales (CPE) in Exposed Hospital Drains in Ontario, Canada
por: Jamal, Alainna, et al.
Publicado: (2019)

Novel Pyridine Bioisostere of Cabozantinib as a Potent c-Met Kinase Inhibitor: Synthesis and Anti-Tumor Activity against Hepatocellular Carcinoma
por: Karmacharya, Ujjwala, et al.
Publicado: (2021)

MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts
por: Zhu, Kaibin, et al.
Publicado: (2021)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

MD1228: Validation of Single Bunch Stability Threshold & MD1751: Instability Studies with a Single Beam
por: Carver, Lee Robert, et al.
Publicado: (2017)

miR-1228 promotes the proliferation and metastasis of hepatoma cells through a p53 forward feedback loop
por: Zhang, Y, et al.
Publicado: (2015)

Run 1228 - Ring 2 - 16th October 1981, Preparation of the Superconducting Low-B for Antiprotons
por: Bryant, P J, et al.
Publicado: (1981)

1228. The Role of Procalcitonin (PCT) and Lactic Acid in Febrile Neutropenic Cancer Patients in an Oncological Emergency Center
por: Chaftari, Patrick, et al.
Publicado: (2020)

1228. Evaluation of the Practice of Switching from Intravenous to Oral Antimicrobial Therapy at King Abdulaziz University Hospital
por: Alharbi, Reem, et al.
Publicado: (2023)

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
por: Hartmaier, Ryan J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bqmhi92238qb4ssineoqqkegc8